What is William Blair's Estimate for Merus FY2027 Earnings?

Key Points

• William Blair has estimated that Merus N.V. will report earnings of ($3.62) per share for FY2027, which is slightly better than the current consensus estimate of ($3.85) per share.
• The stock currently has a "Hold" rating from William Blair and a consensus price target of $92.88 from analysts, with four analysts rating it as a Buy and twelve as Hold.
• Merus recently reported a quarterly earnings miss with an EPS of ($2.23), which was significantly below the consensus estimate of ($1.17).

Merus N.V. (NASDAQ:MRUS - Free Report) - Equities research analysts at William Blair issued their FY2027 earnings estimates for shares of Merus in a research report issued on Monday, September 29th. William Blair analyst M. Phipps anticipates that the biotechnology company will post earnings of ($3.62) per share for the year. William Blair currently has a "Hold" rating on the stock. The consensus estimate for Merus' current full-year earnings is ($3.85) per share. William Blair also issued estimates for Merus' FY2028 earnings at ($3.36) EPS.

A number of other equities analysts also recently commented on the company. Industrial Alliance Securities set a $90.00 price objective on Merus in a report on Monday, August 25th. HC Wainwright downgraded shares of Merus from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $135.00 to $97.00 in a research report on Monday. Barclays restated an "equal weight" rating and set a $97.00 price target (down previously from $112.00) on shares of Merus in a research note on Tuesday. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $97.00 price objective (up previously from $95.00) on shares of Merus in a research note on Monday. Finally, Citigroup cut shares of Merus from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $101.00 to $97.00 in a report on Monday. Four analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat, Merus has an average rating of "Hold" and a consensus price target of $92.88.

Merus Price Performance

MRUS opened at $94.15 on Wednesday. Merus has a fifty-two week low of $33.19 and a fifty-two week high of $94.56. The business has a 50-day moving average of $67.77 and a 200-day moving average of $55.12. The company has a market capitalization of $7.12 billion, a PE ratio of -17.12 and a beta of 1.19.

Merus (NASDAQ:MRUS - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biotechnology company reported ($2.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($1.06). Merus had a negative net margin of 685.64% and a negative return on equity of 50.28%. The firm had revenue of $8.83 million for the quarter, compared to analyst estimates of $9.77 million.

Insider Buying and Selling

In related news, COO Peter B. Silverman sold 25,000 shares of Merus stock in a transaction on Thursday, July 17th. The shares were sold at an average price of $60.00, for a total value of $1,500,000.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last quarter, insiders have sold 48,500 shares of company stock valued at $2,792,500. Company insiders own 3.70% of the company's stock.

Institutional Trading of Merus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRUS. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Merus by 17.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 98,744 shares of the biotechnology company's stock worth $4,152,000 after buying an additional 14,544 shares during the period. California State Teachers Retirement System grew its stake in shares of Merus by 7.5% in the fourth quarter. California State Teachers Retirement System now owns 41,149 shares of the biotechnology company's stock worth $1,730,000 after acquiring an additional 2,872 shares during the last quarter. GAMMA Investing LLC increased its position in Merus by 2,153.6% during the first quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock worth $27,000 after acquiring an additional 603 shares during the period. Harbor Capital Advisors Inc. raised its stake in Merus by 49.0% during the 1st quarter. Harbor Capital Advisors Inc. now owns 64,374 shares of the biotechnology company's stock valued at $2,710,000 after purchasing an additional 21,166 shares during the last quarter. Finally, Avanza Fonder AB bought a new stake in Merus in the 1st quarter valued at $118,000. Institutional investors and hedge funds own 96.14% of the company's stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.